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Janna A van Diepen,1 Anneke Hijmans,1 Triantafyllos Chavakis,3 Wim H Dokter,4 Christine TN Pham,5
Mihai G Netea,1 Charles A Dinarello,1,6 and Leo AB Joosten1
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Department of Internal Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands; 2Nutrition, Metabolism
and Genomics Group, Wageningen University and Research Centre, Wageningen, The Netherlands; 3Department of Clinical
Pathobiochemistry, University Clinic Carl-Gustav-Carus, Technische Universität Dresden, Dresden, Germany; 4Synthon Research
Laboratories, Nijmegen, The Netherlands; 5Department of Medicine, Division of Rheumatology, Washington University School of
Medicine, St. Louis, Missouri, United States of America; 6Department of Medicine, University of Colorado Denver, Aurora, Colorado,
United States of America; *Current affiliation: Hycult Biotech B.V., Uden, The Netherlands

Activation of inflammatory pathways is known to accompany development of obesity-induced nonalcoholic fatty liver disease
(NAFLD), insulin resistance and type 2 diabetes. In addition to caspase-1, the neutrophil serine proteases proteinase 3, neutrophil elastase and cathepsin G are able to process the inactive proinflammatory mediators interleukin (IL)-1β and IL-18 to their
bioactive forms, thereby regulating inflammatory responses. In this study, we investigated whether proteinase 3 is involved in
obesity-induced development of insulin resistance and NAFLD. We investigated the development of NAFLD and insulin resistance
in mice deficient for neutrophil elastase/proteinase 3 and neutrophil elastase/cathepsin G and in wild-type mice treated with the
neutrophil serine proteinase inhibitor human α-1 antitrypsin. Expression profiling of metabolically relevant tissues obtained from
insulin-resistant mice showed that expression of proteinase 3 was specifically upregulated in the liver, whereas neutrophil elastase,
cathepsin G and caspase-1 were not. Neutrophil elastase/proteinase 3-deficient mice showed strongly reduced levels of lipids in
the liver after being fed a high-fat diet. Moreover, these mice were resistant to high–fat–diet-induced weight gain, inflammation
and insulin resistance. Injection of proteinase 3 exacerbated insulin resistance in caspase-1–/– mice, indicating that proteinase
3 acts independently of caspase-1. Treatment with α-1 antitrypsin during the last 10 d of a 16-wk high-fat diet reduced hepatic
lipid content and decreased fasting glucose levels. We conclude that proteinase 3 is involved in NAFLD and insulin resistance
and that inhibition of proteinase 3 may have therapeutic potential.
Online address: http://www.molmed.org
doi: 10.2119/molmed.2016.00033

INTRODUCTION
Nonalcoholic fatty liver disease
(NAFLD) refers to a disease spectrum
ranging from simple steatosis with no
inflammation through hepatic necroinflammation (nonalcoholic steatohepatitis)
to cirrhosis (1). It is strongly associated
with obesity, insulin resistance and
type 2 diabetes (T2D) and has become

the most frequent liver disease
worldwide (1,2).
Over the last decade, it has become
clear that inflammation has an important
role in obesity and NAFLD (2). However,
the detailed underlying mechanisms of
obesity-induced inflammation are not
fully understood. Important modulatory
effects on both immunity and metabolism
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have been attributed to tumor necrosis
factor (TNF), interleukin (IL)-1β and
IL-18 (3). Many cytokines of the IL-1
family are secreted as inactive precursors
and require processing by proteases. One
protease able to process both pro-IL-1β
and pro-IL-18 to their bioactive forms is
caspase-1, a cysteine protease regulated
by a protein complex called the inflammasome. Indeed, recent studies showed
that mice deficient for caspase-1 or individual components of the inflammasome
have improved insulin sensitivity and
decreased liver steatosis in diet-induced
obesity models (4,5). However, production of active IL-1β and IL-18 is not
exclusively dependent on caspase-1.
Other proteases highly important for
processing of cytokine precursors are
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the neutrophil serine proteases. These
proteases, namely neutrophil elastase,
cathepsin G and proteinase 3, are released by neutrophils and are able to
cleave/process membrane-bound TNF,
mature TNF, pro-IL-1β and pro-IL-18,
thereby regulating inflammatory responses (Figure 1). It is also known that
a large proportion of the released serine
proteases bind to the plasma membrane
with their catalytic activity preserved
(6,7). Recent studies showed that mice
deficient for neutrophil elastase are
resistant to high–fat–diet-induced bodyweight gain, insulin resistance (8,9) and
fatty liver (9). Relatively little is known
about proteinase 3 in relation to insulin resistance and NAFLD. One study
reported that a single injection of commercially available proteinase 3 induced
insulin resistance in healthy mice (10).

However, endogenous proteinase 3 has
not been investigated for its capability to
induce insulin resistance and NAFLD in
diet-induced obese animal models.
Proteinase 3 is strongly inhibited by
the human protease inhibitor α-1 antitrypsin, a multifunctional protein with
potent anti-inflammatory properties. It is
primarily synthesized in the liver but is
also expressed in other cell types including neutrophils, monocytes and macrophages. Besides its capacity to inhibit
proteinase 3, α-1 antitrypsin also blocks
neutrophil elastase and cathepsin G
(Figure 1) (11), as well as caspase-1 and
caspase-3 (12,13). In addition, α-1 anti
trypsin enhances the production of
anti-inflammatory mediators such as
IL-10 and IL1-Ra (14). In light of the
recent evidence that both the caspase-1
and the neutrophil serine p
 roteases are

Figure 1. The role of neutrophil serine proteases in inflammation. Following activation,
neutrophils will release their serine proteases in the extracellular environment. A portion of
these released serine proteases will bind to the membrane. Once released, serine proteases (both membrane-bound and in the extracellular environment) are able to process
(activate and/or inactivate) cytokines, thereby regulating inflammation. Human α-1 antitrypsin has potent anti-inflammatory properties. It complexes with proteinase 3, neutrophil
elastase and cathepsin G, thereby preventing their enzymatic activities. It also inhibits
caspase-1 and enhances the production of the anti-inflammatory mediators IL-10 and
IL-1-Ra. All these actions result in a strong anti-inflammatory effect. PR3, proteinase 3; NE,
neutrophil elastase; CG, cathepsin G; Casp-1, caspase-1; IL-1Ra, interleukin 1 receptor
antagonist.

important for inducing insulin resistance
and NAFLD, α-1-antitrypsin treatment
might also be beneficial for the treatment
of these conditions. In this study, we
engaged a number of in vivo approaches
to pursue the hypothesis that endogenous proteinase 3 is important in the
induction of NAFLD and insulin resistance in mouse models of diet-induced
obesity and to assess whether treatment
with α-1 antitrypsin protects against
obesity-induced development of NAFLD
and insulin resistance.
MATERIALS AND METHODS
Animals
Casp-1–/–, ela–/–/ctsg–/– (neutrophil
elastase/cathepsin G double knock-out
mice; NE–/–/CG–/–) and ela–/–/prtn3–/–
(neutrophil elastase/proteinase 3 double
knock-out mice; NE–/–/PR3–/–) were backcrossed to C57BL/6J background for at
least 10 generations and have been described previously (15,16). Age-matched
wild-type C57BL/6J mice were used as
controls and obtained from Charles River
or Jackson Laboratories. Mice were housed
in a pathogen-free facility and maintained
at 23°C with water and food ad libitum and
a 12 h:12 h light:dark cycle (lights on 6 am
to 6 pm). All mice were 10- to 12-wk-old
males at the start of diet intervention.
Animal studies were approved by the
Animal Welfare Committee of the Radboudumc, Nijmegen, The Netherlands
and the Washington University School of
Medicine, St. Louis, Missouri, USA.
Diet Intervention and Treatment
Regime
Male mice received a low-fat diet or a
high-fat diet for 16 wks, providing 10%
or 45% energy percent in the form of
triglycerides (D12450B or D12451; Research Diets). Regarding the experiments
in which mice were treated with α-1
antitrypsin or proteinase 3, a subgroup of
mice receiving a high-fat diet was divided
in bodyweight-matched treatment groups
during the last 2 wks of dietary intervention. These mice were injected five
times (every other day for 10 d)
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intraperitoneally (IP) with either α-1
antitrypsin (Zemaira; 2.0 mg per injection)
or proteinase 3 (0.25 mg/kg; Athens
Research & Technology Inc.) in vehicle
(phosphate-buffered saline (PBS)) or vehicle alone. Also the low–fat-diet control
group was treated with vehicle (five times
every other day) for the last 10 d of
dietary intervention. Insulin sensitivity
was assessed by insulin tolerance tests
and oral glucose tolerance tests. Mice
were fasted for 4 h and overnight, respectively, before IP injection with insulin
(0.75 U/kg bodyweight) or oral glucose
administration (2 g/kg D glucose; Life
Technologies). Blood samples were taken
by tail-cut at baseline and after 15, 30, 45,
60, 90 and 120 min of insulin or glucose
administration. Blood glucose concentrations were measured with a blood glucose
meter (Accu-Chek Avia; Roche Diagnostics). At the end of the experiments, blood
was collected in heparin-coated tubes and
centrifuged to collect plasma. Liver and
adipose tissue were weighed and collected
for further analysis.
Histology/Immunohistochemistry
Hematoxylin and eosin (HE) staining
of sections and detection of F4/80positive macrophages were done using
standard protocols. Quantification of
lipid droplets in HE liver sections was
performed by using the ImageJ software
(http://rsbweb.nih.gov). Macrophages
and crown-like structures were counted
in four images per sample. Sections were
scored in a blinded fashion.
Liver Triglycerides
For measuring liver triglycerides,
l0% liver homogenates were prepared in
buffer containing 250 nmol/L sucrose,
1 mmol/L EDTA and 10 mmol/L
Tris-HCL at pH 7.5. Triglycerides were
determined enzymatically following
manufacturers’ protocols (Liquicolor;
Human GmbH).
RNA Isolation and Quantitative PCR
Total RNA was isolated using TRIzol
reagent (Life Technologies Europe BV)
and quantity was controlled using a

NanoDrop spectrophotometer (NanoDrop
Technologies). Total RNA (1 μg) was
reverse transcribed (iScript; Bio-Rad Laboratories) and quantitative polymerase
chain reaction (qPCR) was performed
by SYBR Green-based quantification
(Applied Biosystems). Primers were developed using Primer3 (Supplementary
Table S1; http://primer3.ut.ee/). Primer
pairs were exon-spanning. The genes
Gapdh and B2m were chosen as endogenous controls. Differences in expression
were calculated by the 2ΔΔCt method (17).
Statistical Analysis
Data are represented as mean ± SEM
unless stated otherwise. Data were analyzed using, as appropriate, the Student
t test or analysis of variance followed
by the Tukey post hoc test (GraphPad
Prism 5.0). When necessary, results were
log-transformed to normalize the data. A
p value <0.05 was considered significant.
All supplementary materials are available
online at www.molmed.org.
RESULTS
Proteinase 3 Expression Is Increased
in Livers from High–Fat–Diet-Induced
Insulin-Resistant Mice
To explore the role of proteinase 3 in
diet-induced NAFLD and insulin resistance, we first examined proteinase
3 messenger RNA (mRNA) expression in
liver tissues obtained from independent
studies investigating NAFLD and insulin
resistance in mice. Relative expression
of proteinase 3 (Prtn3) in the liver was
increased after 4 wks of high–fat-diet
feeding (2.7-fold induction; p = 0.0096).
Noticeably, caspase-1, neutrophil elastase (Elane) and cathepsin G (Ctsg) gene
expression levels were not affected
(Figure 2A). In addition, whole-genome
expression profiling results showed that
proteinase 3 expression was induced
more than 80-fold (corrected p = 3.78E-08)
in livers from arthritic mice that showed
inflammatory-induced insulin resistance.
Caspase-1, neutrophil elastase and cathepsin G expression were not affected when
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compared with controls (18) (microarray
data available; www.ebi.ac.uk/arrayexpress; accession number E-MTAB-1765).
These results were validated by qPCR
analysis (Figure 2B). The observation
that proteinase 3 mRNA expression, but
not caspase-1, neutrophil elastase and
cathepsin G mRNA expression, is upregulated in livers from animals with dietand inflammation-induced NAFLD and
insulin resistance suggests an unique
role of this protease in the liver.
NE–/–/CG–/– and NE–/–/PR3–/– Mice
Have Reduced Levels of Lipids in
the Liver as well as Improved Insulin
Sensitivity and Glucose Tolerance,
Independently of Bodyweight
To further investigate the role of
neutrophil serine proteases, especially
proteinase 3, in diet-induced NAFLD
and insulin resistance, we performed a
16-wk high–fat-diet intervention study
in which wild-type mice and animals deficient for ela/ctsg (NE–/–/CG–/–) and ela/
prtn3 (NE–/–/PR3–/–) were compared (16).
Before the start of the diet intervention, no differences in bodyweight were
observed between the three genotypes.
High–fat-diet feeding induced weight
gain in all groups, although weight gain
after high-fat diet was significantly less
in both knock-out mice as compared
with the wild-type animals (Figure 3A).
No differences in weight gain were observed between the two double knockout genotypes. No differences in food intake were observed between the groups.
To assess insulin sensitivity, insulin
tolerance tests and oral glucose tolerance
tests were performed. Both NE–/–/CG–/– and
NE–/–/PR3–/– mice were more insulin sensitive after high-fat diet when compared
with wild-type mice. Insulin tolerance
test area under the curve (AUC) values
were significantly lower in NE–/–/CG–/–
(p < 0.0001) and NE–/–/PR3–/– mice
(p < 0.0001) when compared with the
wild-type controls. Also the oral glucose
tolerance tests AUC values were decreased
in NE–/–/CG–/– (p = 0.02) and NE–/–/PR3–/–
mice (p < 0.0001) when compared with
those of wild-type mice, indicating
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Figure 2. Relative mRNA expression of proteinase 3, caspase-1, neutrophil elastase and cathepsin G in liver. (A) Relative mRNA expression of proteinase 3, caspase-1, neutrophil elastase and cathepsin G after 4 wks of diet intervention. (B) Relative mRNA expression of
proteinase 3, caspase-1, neutrophil elastase and cathepsin G in nonarthritic and arthritic mice. PR3, proteinase 3; NE, neutrophil elastase; CG, cathepsin G; LFD, low-fat diet; HFD, high-fat diet; **significant difference p ≤ 0.01; NS, nonsignificant.

improved glucose tolerance. Blood glucose
levels were lower in NE–/–/PR3–/– mice
after 120 min during the insulin tolerance
test and after 60 min during the oral glucose tolerance test when compared with
those of NE–/–/CG–/– mice (p = 0.0034 and
p = 0.0374, respectively). However, differences in AUC values between NE–/–/CG–/–
and NE–/–/PR3–/– mice were not significant
for both the insulin tolerance test and the
oral glucose tolerance test (Figure 3B).
No differences in plasma insulin levels
were observed between the three groups
(Figure 3C).
NAFLD was assessed by quantifying
lipid droplets in HE-stained liver sections. Large differences in the quantity
of lipid droplets in the liver were observed between the three genotypes after

high-fat diet. Both NE–/–/CG–/– and NE–/–/PR3–/–
mice had a significantly reduced liver
weight and reduced lipid droplets in the
liver when compared with wild-type mice
(p = 0.0035 and p < 0.0001, respectively).
In accordance, liver triglyceride levels
were significantly decreased in both
NE–/–/CG–/– (p = 0.0001) and NE–/–/PR3–/–
(p < 0.0001) mice when compared with
those of wild-type mice (Figures 3D, E).
Strikingly, and despite similar bodyweight gain upon high–fat-diet feeding,
NE–/–/PR3–/– mice displayed a significant reduction in liver weight and lipid
droplet accumulation in the liver when
compared with NE–/–/CG–/– mice
(p < 0.0001).
To identify molecular pathways that
may be responsible for the observed

reduction in lipid accumulation in the
liver, relative expression of several genes
involved in lipid metabolism was measured (Figure 3F). Expression of Cd36
(Cd36 molecule), involved in fatty acid
uptake and transport, was significantly
decreased in NE–/–/PR3–/– (p = 0.0073),
but not in NE–/–/CG–/– mice, when compared with wild-type mice. Fabp1 (fatty
acid-binding protein 1), a gene involved
in intracellular fatty acid transport, was
downregulated in NE–/–/CG–/– mice
(p = 0.0297), but not in NE–/–/PR3–/– mice.
In addition, two genes involved in lipogenesis (diacylglycerol O-acyltransferase
1 [Dgat1] and fatty acid synthase [Fas])
were significantly downregulated in
NE–/–/PR3–/– (p < 0.0001 and p = 0.0002,
respectively), but not in NE–/–/CG–/–
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mice. Also the genes Pparα (peroxisome
proliferator-activated receptor α) and
Cpt1a (carnitine palmitoyltransferase 1A, liver), both involved in fatty
acid oxidation, were downregulated in

NE–/–/PR3–/–, but not in NE–/–/CG–/– mice
compared with wild-type animals
(p = 0.0065 and p = 0.0037, respectively).
Overall, gene expression data suggest
that processes involved in fatty acid

uptake and lipogenesis are less active
in livers from NE–/–/PR3–/– mice when
compared with NE–/–/CG–/– mice and
wild-type mice. Altogether, our interim
conclusion is that these results point

Figure 3. Improved NAFLD status and metabolic profiles in NE–/–/CG–/– and NE–/–/PR3–/– mice after a high-fat diet. (A) Bodyweight development of wild-type (n = 10), NE–/–/CG–/– (n = 15) and NE–/–/PR3–/– (n = 15) mice during diet intervention. (B) Insulin tolerance test and ITT AUC
values, oral glucose tolerance test and oGTT AUC values of wild-type, NE–/–/CG–/– and NE–/–/PR3–/–. (C) Plasma insulin levels. (D) HE staining
of liver sections. (E) Percentage of lipid droplets in HE-stained liver sections, liver weights and liver triglycerides levels. (F) Relative mRNA expression of Cd36, Fabp1, Dgat1, Fas, Ppar α and Cpt1a in liver. HFD, high-fat diet; WT, wild-type; ITT, insulin tolerance test; oGTT, oral glucose
tolerance test; TG, triglycerides; *significant difference p ≤ 0.05; **significant difference p ≤ 0.01; ***significant difference p ≤ 0.001.
Continued on the next page
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Figure 3. Continued.
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toward an important role for neutrophil
serine proteases in the development of
high–fat–diet-induced obesity, insulin resistance, glucose intolerance and NAFLD.
Moreover, the absence of proteinase 3
specifically causes an additional reduction in lipid accumulation in the liver as
compared with cathepsin G.
NE–/–/CG–/– and NE–/–/PR3–/– Mice
Displayed Reduced Inflammation in
Response to High–Fat-Diet Feeding
Given the role of neutrophil serine proteases in the activation of inflammatory
processes, we next investigated inflammation in white adipose tissue and liver
of NE–/–/CG–/–, NE–/–/PR3–/– and wild-type
mice. Immunohistochemical localization of
F4/80-positive macrophages in white adipose tissue of high–fat–diet-fed mice was
analyzed and showed a strong reduction
in the number of macrophages in both
NE–/–/CG–/– (p < 0.0001) and NE–/–/PR3–/–
mice (p < 0.0001) when compared with
wild-type mice (Figures 4A, B). No differences in the weight of white adipose
tissue were observed between the groups.
No significant difference in the number of
macrophages was observed between the
two knock-out mice groups. In addition,
the number of crown-like structures that
infiltrated the white adipose tissue was
significantly reduced in both high–
fat–diet-fed NE–/–/CG–/– (p = 0.0002) and
NE–/–/PR3–/– mice (p < 0.0001) when compared with wild-type mice (Figure 4C).
No differences in the number of crownlike structures were observed between
NE–/–/CG–/– and NE–/–/PR3–/– mice.
Subsequently, we assessed the
inflammatory status of white adipose
tissue ex vivo. After isolation, white adipose tissue from all three genotypes
was cultured in medium for 24 h and
the release of IL-6 and KC (CXCL1) was
measured. Excretion of IL-6, an interleukin induced by IL-1β, was significantly
reduced in white adipose tissue explants
of NE–/–/CG–/– mice (p = 0.069). IL-6 excretion was also reduced in white adipose
tissue explants of NE–/–/PR3–/– mice when
compared with those of wild-type mice
but differences were not statistically

significant. No differences in IL-6 levels
were observed between the two knock-out
groups (Figure 4D). Also no differences
in KC (CXCL1) levels were observed
between the three experimental groups
(Figure 4E).
To investigate whether the reduction
in lipid accumulation in livers from
NE–/–/CG–/– and NE–/–/PR3–/– mice correlated
with the inflammatory status in the liver,
we examined the relative expression of
several inflammatory genes (Figure 4F).
Interestingly, while mRNA expression
of IL-1β and Cd68 molecule (Cd68), a
marker for monocyte and macrophage
infiltration, were significantly downregulated in NE–/–/PR3–/– mice when compared with wild-type mice (p = 0.0325 and
p < 0.0001, respectively), no reduction
was observed in livers of NE–/–/CG–/–
mice versus wild-type mice. A similar
trend was observed for IL6 and monocyte chemotactic protein 1 (Mcp-1). The
anti-inflammatory gene interleukin-1
receptor antagonist (IL-1Ra) was downregulated in NE–/–/PR3–/– mice when
compared with wild-type mice
(p = 0.0085). To conclude this section,
these results show that NE–/–/CG–/–
and NE–/–/PR3–/– mice display reduced
inflammation in adipose tissue as
compared with wild-type mice. Interestingly, only NE–/–/PR3–/– mice, but not
NE–/–/CG–/– mice, showed reduced hepatic inflammation, suggesting that proteinase 3 specifically plays an important
role in the activation of inflammatory
pathways in the liver.
Proteinase 3 Induces In Vivo Insulin
Resistance
To investigate whether the induction
of insulin resistance and NAFLD by
proteinase 3 acts through a mechanism
independently of caspase-1, we treated
caspase-1–/– mice with proteinase 3
(0.25 mg/kg in vehicle) or vehicle (PBS)
during the last 10 d of a 16-wk high-fat
diet. No differences in bodyweight were
observed between vehicle- and proteinase
3-treated animals (Figure 5A). Casp-1–/–
mice injected with proteinase 3 had
significantly higher fasting glucose levels
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at baseline (p = 0.0021) (Figure 5B) and
were more insulin resistant, as assessed
by the insulin tolerance test, when compared with casp-1–/– mice injected with
vehicle (p = 0.021) (Figure 5C). Plasma
insulin levels tended to be higher in
proteinase 3-treated mice but differences
were not statistically significant (Figure 5D).
The quantity of lipid droplets in the
liver, liver weights and liver triglycerides
were not different between caspase-1–/–
mice treated with vehicle or proteinase 3
(Figures 5E, F). In accordance, proteinase
3 treatment did not affect regulation
of the hepatic lipid metabolism genes
Cd36, Fabp1, Dgat1, Fas, Pparα and Cpt1a
(Supplementary Figure S1). To evaluate
whether proteinase 3 treatment affects
the inflammatory status of white adipose
tissue and liver, macrophage infiltration
and ex vivo secretion of proinflammatory
cytokines were determined, but no differences between vehicle- and proteinase
3-treated animals were observed. In
addition, no differences in expression
were observed for the inflammatory
genes IL-1β, Cd68, IL6, Mcp-1 and IL-1Ra
in either white adipose tissue or liver
(data not shown). These results indicate
that the induction of insulin resistance
by PR3 acts independently of caspase-1.
Moreover, short-term treatment with
proteinase 3 enhances basal glucose
levels and induces insulin resistance
independent of changes in hepatic
lipid metabolism or activation of genes
involved in inflammation. Notably,
bodyweight was not different between
proteinase 3- and vehicle-treated animals, indicating that the observed insulin
resistance is not caused by differences in
bodyweight.
Treatment with Human `-1 Antitrypsin
Decreases Fasting Glucose
Levels and Reduced Lipid Droplet
Accumulation in the Liver
We next investigated whether inhibition of neutrophil serine proteases
would reduce NAFLD and improve insulin resistance in vivo in an established
animal model of diet-induced obesity.
Wild-type C57BL/6J mice were divided

RESEARCH ARTICLE

Figure 4. NE–/–/CG–/– and NE–/–/PR3–/–mice have reduced inflammation after a high-fat diet. (A) Representative images of immunostaining of the macrophage marker F4/80 in white adipose tissue of wild-type, NE–/–/CG–/–and NE–/–/PR3–/– mice. (B) Average number of macrophages per field. (C) Average number of CLS per field. Secretion of (D) IL-6 and (E) KC by white adipose tissue explants. (F) Relative
mRNA expression of IL-1b, Cd68, IL-6, Mcp-1 and IL-1Ra in liver. WT, wild-type; HFD, high-fat diet; CLS, crown-like structures; *significant
difference p ≤ 0.05; **significant difference p ≤ 0.01 ***significant difference p ≤ 0.001; NS, nonsignificant.
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Figure 5. Injected proteinase 3 induces insulin resistance in caspase-1-deficient mice during the last 10 d of a high-fat diet. (A) Bodyweight of caspase-1–/– mice treated with vehicle (n = 10) or proteinase 3 (n = 10) during last 10 d of a high-fat diet. (B) Fasting glucose
levels at baseline. (C) Glucose levels during insulin tolerance test and ITT AUC values. (D) Plasma insulin levels. (E) HE staining of liver sections. (F) Percentage of lipid droplets in HE-stained liver sections, liver weights and liver triglycerides. ITT, insulin tolerance test; PR3,
proteinase 3; TG, triglycerides; *significant difference p ≤ 0.05; **significant difference p ≤ 0.01.

in bodyweight-matched treatment
groups and treated (IP injection every
other day) either with α-1 antitrypsin
(Zemaira 2.0 mg/mouse) or vehicle (PBS)
during the last 10 d of a 16-wk high–
fat–diet-feeding period. As a control,
low–fat–diet-fed mice were also treated
with vehicle.

After treatment, no differences in
bodyweight were observed between
vehicle- and α-1-antitrypsin-treated mice
(Figure 6A). However, fasting glucose
levels decreased substantially after
α-1-antitrypsin treatment and were comparable with the fasting glucose levels of
mice receiving the low-fat diet (p = 0.001)
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(Figure 6B). Despite the decreased fasting glucose levels in the α-1-antitrypsintreated group, the insulin tolerance test
AUC values and insulin levels did not
differ between the two high-fat diet
groups (Supplementary Figures S2A, B).
NAFLD was assessed by quantifying
lipid droplets in HE-stained liver
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Figure 6. Treatment with α-1 antitrypsin improves NAFLD status and reduces fasting glucose during the last 10 d of a high-fat diet.
(A) Bodyweight of mice after a low-fat diet and treated with vehicle and after a high-fat diet treated with either vehicle or α-1 antitrypsin. (B) Fasting glucose levels. (C) HE staining of liver sections. (D) Percentage of lipid droplets in HE-stained liver sections, liver weights
and liver triglycerides. LFD, low-fat diet; HFD, high-fat diet; hAAT, human α-1 antitrypsin; TG, triglycerides; **significant difference p ≤ 0.01;
***significant difference p ≤ 0.001; NS, nonsignificant.

sections. Lipid droplet accumulation
in the liver was significantly lower in
mice treated with α-1 antitrypsin when
compared with mice treated with vehicle

(p = 0.003). Liver weights and triglyceride levels were not different between
groups after α-1-antitrypsin treatment
(Figures 6C, D).

To identify the underlying pathways that may be responsible for the
observed reduction in lipid accumulation in the liver after α-1-antitrypsin
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treatment, the relative expression of
the genes Cd36, Fabp1 (fatty acid transport
and uptake), Dgat1, Fas (lipogenesis),
Pparα and Cpt1a (fatty acid oxidation)
was evaluated in liver tissue. Although
these genes were not significantly regulated after α-1-antitrypsin treatment,
a trend toward increased expression
was observed in the α-1-antitrypsintreated group for Dgat1, Fas, Pparα
and Cpt1a (Supplementary Figure S3).
Overall, these results show that inhibition of neutrophil serine proteases
by α-1 antitrypsin improves fasting
glucose and reduces lipid droplet accumulation in the liver of mice fed a
high-fat diet.

Treatment with `-1 Antitrypsin
Reduces Macrophage Influx into
the Adipose Tissue
It is a well-known fact that α-1 antitrypsin has strong anti-inflammatory
properties (14). We therefore investigated
whether α-1 antitrypsin is capable of
reducing low-grade inflammation as it
is seen in obesity. The number of F4/80-
positive macrophages that infiltrated the
white adipose tissue was substantially
reduced in high–fat–diet-fed mice treated
with α-1 antitrypsin when compared with
high–fat–diet-fed mice treated with vehicle
(p = 0.0405) (Figures 7A, B). In line with
the reduction in macrophage infiltration,
there was a clear trend toward a reduction

in the number of crown-like structures in
adipose tissue of α-1-antitrypsin-treated
mice (Figure 7C). Ex vivo culturing of
white adipose tissue revealed no effect of
α-1-antitrypsin treatment on the secretion
of IL-6 and KC (Figures 7D, E).
Subsequently, we investigated
whether this reduced inflammatory
status in the adipose tissue was also
present in the liver after α-1-antitrypsin
treatment. The relative expression of
the genes IL1b, Cd68, IL6, Mcp-1 and
IL1Ra was evaluated, but no differences
between vehicle- and α-1-antitrypsintreated mice were observed (data not
shown). In addition, no differences
in relative expression between the

Figure 7. Treatment with human α-1 antitrypsin reduces macrophage infiltration into the adipose tissue during the last 10 d of a highfat diet. (A) Representative images of immunostaining of the macrophage marker F4/80 in white adipose tissue of low–fat–diet-fed
mice treated with vehicle, high–fat–diet-fed mice treated with vehicle and high–fat–diet-fed mice treated with human α-1 antitrypsin.
(B) Average number of macrophages per field. (C) Average number of crown-like structures (CLS) per field. Secretion of (D) IL6 and
(E) KC by white adipose tissue explants. LFD, low-fat diet; HFD, high-fat diet; hAAT, human α-1 antitrypsin; CLS, crown-like structures;
*P ≤ 0.05; NS, nonsignificant.
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groups were observed for the genes
proteinase 3 (Prtn3), neutrophil elastase
(Elane) and cathepsin G (Ctsg) (data
not shown). Overall, these results show
that treatment with α-1 antitrypsin
reduces adipose tissue macrophage
content.
DISCUSSION
Our results demonstrate that neutrophil
serine proteases have a prominent role in
the development of NAFLD and insulin
resistance. We also show that treatment
with the neutrophil serine proteases inhibitor α-1 antitrypsin strongly reduces
lipid droplets in the liver, improves fasting glucose levels and decreases adipose
tissue inflammation in mice with high–
fat–diet-induced NAFLD and insulin
resistance. Together, these findings provide evidence that proteinase 3 is a novel
mechanism involved in the development
of NAFLD and insulin resistance and that
inhibition of proteinase 3, combined with
inhibition of other neutrophil serine proteases, may have therapeutic potential.
Our results, indicating that neutrophil
serine proteases are involved in the development of insulin resistance and
NAFLD, are supported by others studies
as well. Recently, it was reported that
mice deficient for neutrophil elastase
were resistant to high–fat–diet-induced
inflammation, insulin resistance (8,9)
and NAFLD (9). Concerning proteinase
3, relatively little is known and studies
investigating the role of endogenous proteinase 3 in models for obesity, insulin
resistance and NAFLD were lacking. Our
results provide evidence that, in addition to neutrophil elastase, endogenous
proteinase 3 is also important for high–
fat–diet-induced development of obesity,
insulin resistance and NAFLD. Both
NE–/–/CG–/– and NE–/–/PR3–/– mice were
more insulin sensitive when compared
with wild-type mice. Regarding NAFLD,
liver lipid content and liver weights were
reduced in NE–/–/CG–/– mice, and this
effect was even stronger in NE–/–/PR3–/–
mice. Given that the absence of proteinase 3 specifically causes an additional
reduction in lipid content in the liver as

compared with cathepsin G, our results
point out to a prominent role for proteinase 3 in the development of NAFLD.
This additional effect of proteinase 3 is
also seen at the level of transcription.
Relative expression of genes involved in
fatty acid uptake and transport (Cd36),
lipogenesis (Dgat1, Fas) and fatty acid
oxidation (Pparα, Cpt1a) was downregulated in livers from NE–/–/PR3–/– mice
when compared with those of wild-type
and NE–/–/CG–/– mice. These results suggest that lipid metabolism pathways in
the liver are, at least partly, regulated by
proteinase 3. We hypothesized that neutrophil serine proteases induce metabolic
disturbances by altering and/or activating inflammatory processes. Indeed,
our results showed that mice deficient
for NE/CG and NE/PR3 had, in addition
to the improved metabolic profile, a
reduced adipose tissue macrophage infiltration after high–fat-diet feeding when
compared with wild-type mice. Also
here, the results suggest a prominent
role for proteinase 3 in the liver as the
relative expression of the inflammatory
genes IL1b, Cd68 and IL1ra was downregulated in livers from NE–/–/PR3–/– mice
when compared with those of w
 ild-type
and NE–/–/CG–/– mice. Also IL6 and Mcp1
showed a strong tendency toward downregulation in livers from NE–/–/PR3–/–
mice. These results strengthen the hypothesis that neutrophil serine proteases
induce metabolic dysfunction by the
activation and/or prolongation of
inflammatory processes.
The influence of weight differences
between experimental groups is, as
a confounding factor, a problem for
studying metabolic disorders. Although
bodyweight was different between wildtype and the two knock-out groups, no
difference in bodyweight was observed
between NE–/–/CG–/– and NE–/–/PR3–/–
mice. Also no differences in bodyweight
were observed between α-1-antitrypsinand vehicle-treated mice. These results
indicate that the improved metabolic
profiles in NE–/–/PR3–/– mice and α-1
antitrypsin-treated mice were not caused
by differences in bodyweight.

Given the prominent role of IL-1β in
inflammation-induced T2D and NAFLD
and the role of neutrophil serine proteases in processing pro-IL-1β into its
active form, it is a logical next step to
point out IL-1β as the prime suspect for
the observed metabolic disturbances.
However, that is not necessarily the case.
Besides cytokine processing, neutrophil
serine proteases are also known to
regulate other molecular mechanisms involved in inflammation. Neutrophil serine proteases are able to proteolytically
modify chemokines such as, for instance,
CXC-chemokine 8 (CXCL8) (19). They
also play a role in receptor activation (20)
and have been shown to cleave cellsurface adhesion molecules, thereby
potentially participating in neutrophil
migration (21). These examples indicate
that, in addition to the processing of
pro-IL-1β, neutrophil serine proteases
also regulate many other inflammatory
pathways that might be involved in the
induction of metabolic complications.
In recent years, it has become evident
that NAFLD and T2D are complex disorders in which multiple mechanisms are
involved. In search for new therapeutics,
the effectiveness of targeting a single
protein may therefore be limited and a
more comprehensive approach is needed
that integrates multiple mechanisms of
action. In this perspective, α-1 antitrypsin is of particular interest as it targets
multiple inflammatory proteins known
to be involved in obesity-induced development of T2D and NAFLD. Given the
recent evidence that caspase-1 (5) and
both neutrophil elastase (8,9) and proteinase 3 (this study) are involved in the
development of T2D and NAFLD, it is
very well possible that α-1 antitrypsin therapy would be beneficial for the treatment of these conditions. Mansuy-Aubert
et al. showed that transgenic mice overexpressing α-1 antitrypsin are protected against high–fat–diet-induced
insulin resistance and NAFLD (9). Our
results showed that α-1-antitrypsin
treatment reduced liver lipid content and
improved fasting glucose. In addition,
α-1-antitrypsin treatment reduced
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obesity-induced inflammation. These
results support our hypothesis that
α-1-antitrypsin treatment is capable of
improving metabolic status by reducing
inflammation.
One limitation of this study is that
a solo proteinase 3 knock-out mouse
model is not available. As a result, it is
difficult to exactly discriminate between
effects induced by proteinase 3 or
neutrophil elastase. Another limitation is
that we were able to test only one dose
of α-1 antitrypsin. We suggest that in
future experiments multiple doses of α-1
antitrypsin need to be tested, thereby
providing the opportunity to study its
effects in a dose-response manner.
CONCLUSION
We identified proteinase 3 as a new factor involved in NAFLD and insulin resistance. Inhibition of proteinase 3 and other
neutrophil serine proteases by α-1 antitrypsin reduced lipid content in the liver
and decreased fasting glucose levels and
therefore may have therapeutic potential.
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